Eyetronic Therapie

About:

Eyetronic Therapie is a MedTech company that developed a stimulation system for the treatment of neurologically caused impairments

Website: https://eyetronic-therapie.de/

Twitter/X: Eyetronic_

Top Investors: HTGF | High-Tech Gruenderfonds, Earlybird Venture Capital, Investitionsbank des Landes Brandenburg, Brandenburg Kapital, MedTech Innovator

Description:

EBS Technologies is a medical device company that has developed a stimulation system for the treatment of neurologically caused impairments such as visual field loss. Such impairments can be the result of stroke, traumatic-brain-injury, glaucoma or several other diseases. The EBS Therapy (previously: NEXT WAVE™Therapy) is a non-invasive optic nerve stimulation deploying weak electrical currents, resulting in neuroregeneration and neuroprotection. Low-voltage electrical pulses are administered at frequencies and amplitudes identified as optimal for each patient, allowing retinal ganglion cells to regenerate and branch out new axons. The company benefits from more than 15 years of research and clinical experience with more than 1,200 patients. Double blind, randomized studies, as well as clinical observations show that the EBS Therapy can partially restore vision field in patients. In 2013 EBS Technologies received the CE Mark for the stimulation device and started the commercial treatment in 2014. There are currently 8 EBS Treatment centers across Germany and the company is slowly widening the network.

Total Funding Amount:

10.4M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Potsdam, Brandenburg, Germany

Founded Date:

2007-01-01

Contact Email:

therapie(AT)eyetronic.com

Founders:

Anton Fedorov, Bernhard Sabel, Kornelia Sabel

Number of Employees:

11-50

Last Funding Date:

2017-08-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai